sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation

<h4>Background</h4> We investigated the impact of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio to predict short-term risk of preeclampsia on clinical utility and healthcare resource utilisation using real-world data (RWD), and compared findings wit...

Full description

Bibliographic Details
Main Authors: Anne Dathan-Stumpf, Anna Rieger, Stefan Verlohren, Cyrill Wolf, Holger Stepan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870556/?tool=EBI
_version_ 1818491486156619776
author Anne Dathan-Stumpf
Anna Rieger
Stefan Verlohren
Cyrill Wolf
Holger Stepan
author_facet Anne Dathan-Stumpf
Anna Rieger
Stefan Verlohren
Cyrill Wolf
Holger Stepan
author_sort Anne Dathan-Stumpf
collection DOAJ
description <h4>Background</h4> We investigated the impact of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio to predict short-term risk of preeclampsia on clinical utility and healthcare resource utilisation using real-world data (RWD), and compared findings with health economic modelling from previous studies. <h4>Methods and findings</h4> This retrospective analysis compared data from the German population of a multicentre clinical study (PROGNOSIS, n = 203; sFlt-1/PlGF ratio blinded and unavailable for decision-making) with RWD from University Hospital Leipzig, Germany (n = 281; sFlt-1/PlGF ratio used to guide clinical decision-making). A subgroup of the RWD cohort with the same inclusion criteria as the PROGNOSIS trial (RWD prediction only, n = 99) was also included. sFlt-1/PlGF ratio was measured using fully automated Elecsys® sFlt-1 and PlGF immunoassays (cobas e analyser; Roche Diagnostics). A similar proportion of women in the RWD and PROGNOSIS cohorts experienced preeclampsia (14.95% vs. 13.79%; p = 0.7938); a smaller proportion of women in the RWD prediction only cohort experienced preeclampsia versus PROGNOSIS (6.06%; p = 0.0526). In women with preeclampsia, median gestational age at delivery (weeks) was comparable in the RWD and PROGNOSIS cohorts (34.0 vs. 34.3, p = 0.5895), but significantly reduced in the RWD prediction only cohort versus PROGNOSIS (27.1, p = 0.0038). sFlt-1/PlGF ratio at baseline visit was not statistically significantly different for the RWD and PROGNOSIS cohorts, irrespective of preeclampsia outcome. Hospitalisations for confirmed preeclampsia were significantly shorter in the RWD cohort versus PROGNOSIS (median 1 vs. 4 days, p = 0.0093); there was no significant difference between RWD prediction only and PROGNOSIS (3 days, p = 0.9638). All-cause hospitalisations were significantly shorter in the RWD (median 1 day; p<0.0001) and RWD prediction only (1 day; p<0.0001) cohorts versus PROGNOSIS (3 days). <h4>Conclusions</h4> This study supports the findings of previous studies, showing that routine clinical use of the sFlt-1/PlGF ratio may result in shorter duration of hospitalisations, with potential economic benefits.
first_indexed 2024-12-10T17:31:27Z
format Article
id doaj.art-30ffe7e77deb4db4bcaaa0906dfa1e6a
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-10T17:31:27Z
publishDate 2022-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-30ffe7e77deb4db4bcaaa0906dfa1e6a2022-12-22T01:39:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01172sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisationAnne Dathan-StumpfAnna RiegerStefan VerlohrenCyrill WolfHolger Stepan<h4>Background</h4> We investigated the impact of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio to predict short-term risk of preeclampsia on clinical utility and healthcare resource utilisation using real-world data (RWD), and compared findings with health economic modelling from previous studies. <h4>Methods and findings</h4> This retrospective analysis compared data from the German population of a multicentre clinical study (PROGNOSIS, n = 203; sFlt-1/PlGF ratio blinded and unavailable for decision-making) with RWD from University Hospital Leipzig, Germany (n = 281; sFlt-1/PlGF ratio used to guide clinical decision-making). A subgroup of the RWD cohort with the same inclusion criteria as the PROGNOSIS trial (RWD prediction only, n = 99) was also included. sFlt-1/PlGF ratio was measured using fully automated Elecsys® sFlt-1 and PlGF immunoassays (cobas e analyser; Roche Diagnostics). A similar proportion of women in the RWD and PROGNOSIS cohorts experienced preeclampsia (14.95% vs. 13.79%; p = 0.7938); a smaller proportion of women in the RWD prediction only cohort experienced preeclampsia versus PROGNOSIS (6.06%; p = 0.0526). In women with preeclampsia, median gestational age at delivery (weeks) was comparable in the RWD and PROGNOSIS cohorts (34.0 vs. 34.3, p = 0.5895), but significantly reduced in the RWD prediction only cohort versus PROGNOSIS (27.1, p = 0.0038). sFlt-1/PlGF ratio at baseline visit was not statistically significantly different for the RWD and PROGNOSIS cohorts, irrespective of preeclampsia outcome. Hospitalisations for confirmed preeclampsia were significantly shorter in the RWD cohort versus PROGNOSIS (median 1 vs. 4 days, p = 0.0093); there was no significant difference between RWD prediction only and PROGNOSIS (3 days, p = 0.9638). All-cause hospitalisations were significantly shorter in the RWD (median 1 day; p<0.0001) and RWD prediction only (1 day; p<0.0001) cohorts versus PROGNOSIS (3 days). <h4>Conclusions</h4> This study supports the findings of previous studies, showing that routine clinical use of the sFlt-1/PlGF ratio may result in shorter duration of hospitalisations, with potential economic benefits.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870556/?tool=EBI
spellingShingle Anne Dathan-Stumpf
Anna Rieger
Stefan Verlohren
Cyrill Wolf
Holger Stepan
sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation
PLoS ONE
title sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation
title_full sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation
title_fullStr sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation
title_full_unstemmed sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation
title_short sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation
title_sort sflt 1 plgf ratio for prediction of preeclampsia in clinical routine a pragmatic real world analysis of healthcare resource utilisation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870556/?tool=EBI
work_keys_str_mv AT annedathanstumpf sflt1plgfratioforpredictionofpreeclampsiainclinicalroutineapragmaticrealworldanalysisofhealthcareresourceutilisation
AT annarieger sflt1plgfratioforpredictionofpreeclampsiainclinicalroutineapragmaticrealworldanalysisofhealthcareresourceutilisation
AT stefanverlohren sflt1plgfratioforpredictionofpreeclampsiainclinicalroutineapragmaticrealworldanalysisofhealthcareresourceutilisation
AT cyrillwolf sflt1plgfratioforpredictionofpreeclampsiainclinicalroutineapragmaticrealworldanalysisofhealthcareresourceutilisation
AT holgerstepan sflt1plgfratioforpredictionofpreeclampsiainclinicalroutineapragmaticrealworldanalysisofhealthcareresourceutilisation